Abstract Number: 1205 • 2015 ACR/ARHP Annual Meeting
The Spectrum of Early RA Practice Across the Globe: Results from a Multinational Cross Sectional Survey
Background/Purpose: Early diagnosis & treatment are crucial to the management of rheumatoid arthritis (RA). Despite this, the approach to early RA management appears to be…Abstract Number: 2669 • 2015 ACR/ARHP Annual Meeting
Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy
Background/Purpose: AM stiffness is a common yet under-appreciated symptom in RA. The longitudinal impact of AM stiffness has not been previously investigated. This study evaluated…Abstract Number: 2552 • 2014 ACR/ARHP Annual Meeting
Effectiveness and Safety of Low-Dose Cyclosporine a in Patients with Primary Sjögren’s Syndrome (pSS) with Articular Involvement – Results of a Pilot Study
Background/Purpose Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, where musculoskeletal manifestations are usually treated by symptomatic measures and different conventional DMARDs by off-label…Abstract Number: 1435 • 2014 ACR/ARHP Annual Meeting
Changes in the Types and Prognoses of Infections Complicated in RA Patients during the Last 15 Years, in Japan.
[Background/Purpose ] Infliximab was introduced in 2002 as the first biological DMARD (bDMARD) in Japan. Currently, 5 TNF inhibitors, tocilizumab, and abatacept are available. Tacrolimus…Abstract Number: 2520 • 2014 ACR/ARHP Annual Meeting
Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide
Background/Purpose . Leflunomide is a disease modifying anti-rheumatic drug that is used in the treatment of rheumatoid arthritis (RA). Leflunomide is converted to teriflunomide by the…Abstract Number: 1358 • 2014 ACR/ARHP Annual Meeting
A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women
Background/Purpose The use of anti-rheumatic drugs in pregnancy is often complicated by concerns over their potential for adverse effects. Given that rheumatic diseases often affect…Abstract Number: 2525 • 2014 ACR/ARHP Annual Meeting
Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial
Background/Purpose: The introduction of TNF inhibitors has improved the treatment of RA, but at a substantial cost. The randomized Swefot trial compared the addition of…Abstract Number: 1242 • 2014 ACR/ARHP Annual Meeting
Switching Biologic Agents in Refractory Adult-Onset Still’s Disease: Efficacy and Safety in a Cohort of 20 Patients at a Single Referral Center
Background/Purpose No data is available on the long-term clinical outcome of Adult-Onset Still's Disease (AOSD) patients treated with biological drugs, nor on the efficacy and…Abstract Number: 2494 • 2014 ACR/ARHP Annual Meeting
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
Background/Purpose: Few rheumatoid arthritis (RA) patients are managed successfully with a single disease modifying anti-rheumatic drug (DMARD). This investigation determined the prevalence and clinical…Abstract Number: 944 • 2014 ACR/ARHP Annual Meeting
Predict the Chance of Remission for Your RA Patient in Real Life
Background/Purpose: Clinical remission (REM) is the treatment target in rheumatoid arthritis (RA), and there are several composite REM criteria available. Knowledge on how disease duration affects REM…Abstract Number: 2419 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Medications in Active Rheumatoid Arthritis: A Systematic Review
Background/Purpose: In the last decade, biologic medications have transformed the management of RA. The effectiveness of these medications has been reported in numerous randomized controlled…Abstract Number: 848 • 2014 ACR/ARHP Annual Meeting
Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients
Background/Purpose Recent studies have found that a high proportion of female rheumatoid arthritis (RA) patients are chronic carriers of high-risk HPV-strains and that these patients…Abstract Number: 2388 • 2014 ACR/ARHP Annual Meeting
DMARD Use after an Initial Acute MI Is Associated with Reduced Risk of a Recurrent Event and Mortality
Background/Purpose Previous studies have suggested that disease modifying anti-rheumatic drugs (DMARDs) may reduce cardiovascular risk among patients with rheumatoid arthritis (RA). This analysis examined whether…Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…Abstract Number: 2368 • 2014 ACR/ARHP Annual Meeting
Impact of Physicians’ Adherence to Treat-to-Target Strategy on Outcomes in Early Rheumatoid Arthritis
Background/Purpose We have previously shown that in early rheumatoid arthritis (RA) remission targeted, intensive combination treatment, regardless of initial infliximab, results in remission in most…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 24
- Next Page »